Compounds that are agonists of alpha2 - 1 receptor agonists preferably alpha 1a / l

摘要

1. Claim 1: compound (1) of general formula,a. X is - S (o) n-O-C (o);A is C1-6alkyl, aryl heteroaryl, hydroxyC1-6alkyl, or - (CH2) p-NRaRb; R1, R2, R3 and R4 are each independently selected from the group consisting of H, halogen, halogen C1-6alkyl, C1-6alkyl, hydroxy, C1-6alkoxy, C1-6alkylthio, (C1-6alkyl ) sulfinyl, (C1-6) alkyl sulfonyl, (C1-6 alkyl) sulfonylamino, (C1-6) alkyl aminosulfonyl, cyano, nitro, -NRaRb, phenyl, benzyl and benzyloxy, where said phenyl rings are optionally substituted by C1-alkyl -6, halogen, cyano, nitro, halogen C1-6alkyl or C1-6 alkoxy; R5 is H, C1-6alkyl, C1-6alkoxy, C1-6alkoxyalkyl, C1-6alkylthio, C1-6alkyl sulfinyl, (C1-6alkyl) sulfonyl, hydroxyC1-6alkyl,C1-6 hydroxy methanol, halogen, C1-6 halogen, C1-6, cyanogen, nrarb, NRC,(C1-6) alkylene -NRaRb, or R5 and A together form a C2-3 alkylene radical; R6 is H or C1-6 alkyl; R 'and R' 'each independently is H or C1-6 alkyl; Ra, Rb, and Rc are each independently selected from the group consisting of H, C1-6alkyl, hydroxyC1-6alkyl, C2-6alkenyl, cycloalkyl (C3-6 )alkyl (C1-6), and arylsulfonyl, or Ra and Rb together with the N to which they are attached may also form a 5- to 7-membered non-aromatic heterocyclic ring, optionally incorporating an additional heteroatom in the ring, selected from N, O, or S; m is 1 or 2; n is 0, 1, or 2 with the proviso that when n is 0, R5 is not -NRaRb; and p is 0, 1, or 2;Or a mixture of an individual isomer, an racemic isomer and a non racemic isomer, a predicted isomer, or a pharmaceutically acceptable salt or solution of these isomers.